European Medicines Agency Supports Roche's Covid-19 Antibody Cocktail
February 26 2021 - 8:05AM
Dow Jones News
By Cecilia Butini
Roche Holding AG said Friday that the European Medicines
Agency's Committee for Medicinal Products for Human Use has issued
an opinion supporting the use of the REGN-COV2 antibody cocktail
proposed for the treatment of Covid-19 patients.
The committee's opinion was produced as the European Medicines
Agency carries out its rolling review process of the treatment,
which is used to speed up the formal marketing application for the
drug and which can be done during a public health emergency, Roche
said. The cocktail is made of casirivimab and imdevimab, two
monoclonal antibodies.
The Swiss pharma major is developing the antibody cocktail
together with partner Regeneron Pharmaceuticals Inc, and the two
companies plan to have more than two million doses available in
2021, Roche said.
Write to Cecilia Butini at cecilia.butini@wsj.com
(END) Dow Jones Newswires
February 26, 2021 07:50 ET (12:50 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Apr 2023 to Apr 2024
